NEW YORK, May 3, 2017 /PRNewswire/ --
Stock-Callers.com has initiated coverage on Array BioPharma Inc. (NASDAQ: ARRY), Celgene Corp. (NASDAQ: CELG), Amgen Inc. (NASDAQ: AMGN), and Cerulean Pharma Inc. (NASDAQ: CERU). Biotechnology companies are engaged in the research and development of biological substances, primarily for the purpose of drug discovery and diagnostic development. Learn more about these stocks by downloading their comprehensive and free reports at:
On Tuesday, shares in Boulder, Colorado headquartered Array BioPharma Inc. saw a drop of 15.98%, ending the day at $7.36. The stock recorded a trading volume of 14.81 million shares, which was above its three months average volume of 3.80 million shares. The Company's shares are trading below their 200-day moving average by 2.35%. Moreover, shares of Array BioPharma, which focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and Asia/Pacific, have a Relative Strength Index (RSI) of 26.54.
On April 27th, 2017, Array BioPharma announced that Shalini Sharp, CFO and Executive Vice President of Ultragenyx Pharmaceutical Inc., joined the Company's Board of Directors on April 27th, 2017. Ms. Sharp has been appointed to the Audit Committee of the Board. ARRY complete research report is just a click away and free at:
Shares in Summit, New Jersey headquartered Celgene Corp. ended the day 0.19% lower at $123.82, with a total trading volume of 3.21 million shares. In the previous three months and since the start of this year, the stock has gained 6.60% and 6.97%, respectively. The Company's shares are trading above their 50-day and 200-day moving averages by 0.06% and 8.03%, respectively. Furthermore, shares of Celgene, which discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide, have an RSI of 48.48.
On April 27th, 2017, Celgene reported operating and financial results for the three months ended March 31st, 2017. Net product sales were $2,950 million, and total revenue was $2,960 million. Based on US GAAP, net income was $941 million for Q1 2017, and diluted earnings per share were $1.16. R&D expenses on a GAAP basis were $995 million; and selling, general, and administrative expenses were $620 million for Q1 2017. The complimentary report on CELG can be downloaded at:
At the close of trading on Tuesday, shares in Thousand Oaks, California headquartered Amgen Inc. finished 0.55% higher at $163.49, with a total trading volume of 3.68 million shares. The stock has advanced 5.07% over the previous three months and 12.59% on an YTD basis. The Company's shares are trading above their 200-day moving average by 1.67%. Additionally, shares of Amgen, which discovers, develops, manufactures, and delivers human therapeutics worldwide, have an RSI of 44.15.
On April 05th, 2017, research firm Jefferies downgraded the Company's stock rating from 'Buy' to 'Hold'.
On April 24th, 2017, Amgen announced an expanded commercial collaboration with Novartis for erenumab, which is being investigated for the prevention of migraine. This expanded commercial collaboration builds on global neuroscience collaboration in Alzheimer's disease and migraine established in 2015 between the two companies. The duo has agreed to combine capabilities to co-commercialize erenumab in the US. Sign up for your complimentary research report on AMGN at:
Waltham, Massachusetts-based Cerulean Pharma Inc.'s shares recorded a trading volume of 891,316 shares at the end of yesterday's session. The stock closed the day 4.23% higher at $0.49. The Company's shares are trading below their 50-day moving average by 56.59%. Additionally, shares of Cerulean Pharma, which develops nanotechnology-based therapeutics in the areas of oncology and other diseases in the US, have an RSI of 37.79. Get free access to your research report on CERU at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA